RevitalVision is a SaaS-based digital health startup operating in the rapidly growing, $52 billion field of vision improvement in the ophthalmic marketplace. The company’s noninvasive technology enhances eyesight neurologically, offering an innovative solution to the 500 million people whose needs are unmet by existing vision treatments.

RevitalVision’s thousands of clinical trial participants and commercial customers have reported and exhibited significant improvement in their vision performance by 2.5 lines on the visual acuity eye chart along with a 100% increase in contrast sensitivity on average for all product categories.

RevitalVision is FDA-cleared for children older than 9 and adults with amblyopia (lazy eye), a leading cause of vision impairment that affects 3% to 5% of the world population. Using brain science and proprietary algorithm-based technology, RevitalVision is clinically validated for use for multiple eye diseases and vision impairments and has been approved for two new unique reimbursement codes by the American Medical Association for the treatment of amblyopia.

RevitalVision provides eye care specialists with a simple, easy-to-use tool to improve patients’ vision beyond optical correction and other current eye treatments, as well as an additional revenue channel. The company also offers eye surgery clinics a valuable tool for reducing unpaid post-surgery visits by cataract and refractive patients who find it difficult to neuro-adapt or who suffer from reduced contrast sensitivity, poor night vision, or side effects such as halo and glare.